Jan 11 (Reuters) - Mesoblast Ltd MSB.AX :
* Phase 3 heart failure trial size to be substantially reduced following FDA
discussions
* Source text for Eikon ID:nGNXMJCAOa
* Further company coverage MSB.AX
Jan 11 (Reuters) - Mesoblast Ltd MSB.AX :
* Phase 3 heart failure trial size to be substantially reduced following FDA
discussions
* Source text for Eikon ID:nGNXMJCAOa
* Further company coverage MSB.AX